1. Home
  2. ESQ vs OMER Comparison

ESQ vs OMER Comparison

Compare ESQ & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$106.27

Market Cap

920.0M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.83

Market Cap

788.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESQ
OMER
Founded
2006
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
920.0M
788.4M
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
ESQ
OMER
Price
$106.27
$9.83
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$120.33
$32.50
AVG Volume (30 Days)
77.9K
698.0K
Earning Date
04-23-2026
05-14-2026
Dividend Yield
0.75%
N/A
EPS Growth
14.20
N/A
EPS
5.87
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$28.65
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
$18.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$69.14
$2.95
52 Week High
$119.86
$17.65

Technical Indicators

Market Signals
Indicator
ESQ
OMER
Relative Strength Index (RSI) 50.34 31.79
Support Level $91.62 $9.31
Resistance Level $106.32 $11.81
Average True Range (ATR) 3.71 0.48
MACD 0.28 -0.13
Stochastic Oscillator 49.89 2.71

Price Performance

Historical Comparison
ESQ
OMER

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: